BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ono Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ono Pharmaceutical's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07222917-306@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0722291
 7)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Chronic Kidney Di
 sease.\nStudy: A Phase IIb Study to Evaluate the Effect of Dapagliflozin i
 n Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in P
 articipants With Chronic Kidney Disease and High Blood Pressure.\nEstimate
 d primary completion: 10 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07222917
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06803823-772@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:ONO-2020: Phase 2 readout est. (NCT06803823)
DESCRIPTION:ONO-2020\, phase 2\, Alzheimer's Disease.\nStudy: A Study of ON
 O-2020 in Patients With Agitation Associated With Alzheimer's Disease Deme
 ntia\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ono-2020#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06803823
URL:https://assetmemo.bio/drug/ono-2020#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06590896-8851@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Xcopri (Cenobamate): Phase 2 readout est. (NCT06590896)
DESCRIPTION:Xcopri (Cenobamate)\, phase 2\, Epilepsy.\nStudy: Safety of Cen
 obamate in Japanese Subjects With Partial Onset Seizures\nEstimated primar
 y completion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cenobamate#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06590896
URL:https://assetmemo.bio/drug/cenobamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06579573-8851@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Xcopri (Cenobamate): Phase 3 readout est. (NCT06579573)
DESCRIPTION:Xcopri (Cenobamate)\, phase 3\, Epilepsy.\nStudy: ONO-2017 Stud
 y Japanese Patients With Primary Generalized Tonic Clonic Seizures.\nEstim
 ated primary completion: 31 January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cenobamate#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06579573
URL:https://assetmemo.bio/drug/cenobamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06946797)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combinatio
 n With Intravenous Ipilimumab and Chemotherapy in Participants With Previo
 usly Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)\
 nEstimated primary completion: 5 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06946797
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03873402)
DESCRIPTION:Nivolumab\, phase 3\, Renal Cell Carcinoma.\nStudy: A Study of 
 Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants 
 With Advanced Kidney Cancer\nEstimated primary completion: 11 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03873402
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270044-1996@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Binimetinib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Binimetinib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06307652-306@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0630765
 2)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patien
 ts With Heart Failure and Impaired Kidney Function\nEstimated primary comp
 letion: 16 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06307652
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03969329-878@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03969329)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Secondary Hyperparathyroid
 ism.\nStudy: A Phase 3 Study of Etelcalcetide in Children With Secondary H
 yperparathyroidism Receiving Hemodialysis\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etelcalc
 etide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03969329
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646276-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06646276)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: A Study to Compare the Efficacy an
 d Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in C
 ombination With Carboplatin Plus Etoposide to That of Atezolizumab With Ca
 rboplatin Plus Etoposide as First-Line Therapy in Participants With Extens
 ive-Stage Small Cell Lung Cancer (TIGOS).\nEstimated primary completion: 1
 7 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06646276
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566380-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04566380)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: ONO-4538 Phase II Rollover Study (
 ONO-4538-98)\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04566380
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948448-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06948448)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to Eva
 luate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®
 \, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in
  Participants With Non-MSI-H/dMMR\, PD-L1 Positive Advanced Colorectal Can
 cer\nEstimated primary completion: 15 February 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06948448
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-306@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0626887
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Investigate the Efficacy and Safety of
  Baxdrostat in Combination With Dapagliflozin on CKD Progression in Partic
 ipants With CKD and High Blood Pressure.\nEstimated primary completion: 24
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapag
 liflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06268873
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594158-8851@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Xcopri (Cenobamate): Phase 3 readout est. (NCT07594158)
DESCRIPTION:Xcopri (Cenobamate)\, phase 3\, Epilepsy.\nStudy: A Study to Ev
 aluate the Safety\, Efficacy\, and PK of ONO-2017 in Japanese Patients Wit
 h POS 2 to 17 Year Olds\nEstimated primary completion: 30 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cenobamate#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07594158
URL:https://assetmemo.bio/drug/cenobamate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662044-306@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0766204
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Type 2 Diabetes.\
 nStudy: A Phase III Study to Investigate the Efficacy and Safety of Elecog
 lipron Alone or in Combination With Dapagliflozin Compared With Placebo in
  Adults With Type 2 Diabetes Mellitus\nEstimated primary completion: 14 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 662044
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07492680)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Study of Navlimetostat (BMS-9865
 04) Monotherapy and in Combination With Other Agents in Participants With 
 Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (Mou
 ntainTAP-5)\nEstimated primary completion: 15 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697197-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06697197)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A Study of BMS-986482 Alone or a
 s Combination Therapy in Participants With Advanced Solid Tumors\nEstimate
 d primary completion: 4 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06697197
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06622941-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06622941)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Study to ONO-4538 in Patients With
  Rhabdoid Tumor\nEstimated primary completion: 31 January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06622941
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03633708-878@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Parsabiv (Etelcalcetide): Phase 3 readout est. (NCT03633708)
DESCRIPTION:Parsabiv (Etelcalcetide)\, phase 3\, Chronic Kidney Disease.\nS
 tudy: A Trial of Etelcalcetide in Pediatric Participants With Secondary Hy
 perparathyroidism and Chronic Kidney Disease on Hemodialysis\nEstimated pr
 imary completion: 31 January 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/etelcalcetide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03633708
URL:https://assetmemo.bio/drug/etelcalcetide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936943-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06936943)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: ONO-4538 Study in Patients With Ri
 chter's Transformation\nEstimated primary completion: 31 July 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06936943
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstimate
 d primary completion: 25 August 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291076-2009@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07291076)
DESCRIPTION:Ipilimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: A St
 udy to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combi
 nation With Ipilimumab in Participants With First-Line Advanced or Unresec
 table Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)\nEstimated primary 
 completion: 15 October 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07291076
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293351-2009@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20291128
DTEND;VALUE=DATE:20291129
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07293351)
DESCRIPTION:Ipilimumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: A Study 
 to Evaluate the Safety\, Tolerability\, and Efficacy of Pumitamig Alone or
  in Combination With Other Agents in Participants With Advanced Renal Cell
  Carcinoma (RCC) (ROSETTA RCC-208)\nEstimated primary completion: 28 Novem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729
 3351
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06677060-306@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20291217
DTEND;VALUE=DATE:20291218
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0667706
 0)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Heart Failure.\nS
 tudy: Phase III Study Investigating Heart Failure and Cardiovascular Death
  With Baxdrostat in Combination With Dapagliflozin\nEstimated primary comp
 letion: 17 December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dapagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06677060
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742723-306@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0674272
 3)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Renal Outcomes and Cardiovascular Mortality Stu
 dy to Investigate the Efficacy and Safety of Baxdrostat in Combination Wit
 h Dapagliflozin in Participants With Chronic Kidney Disease and High Blood
  Pressure\nEstimated primary completion: 18 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06742723
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624305-306@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0762430
 5)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Chronic Kidney Di
 sease.\nStudy: A Phase III Study to Evaluate the Effect of Balcinrenone/Da
 pagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)\nEstimated 
 primary completion: 1 July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dapagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07624305
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561386-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06561386)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy v
 s Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-
 small Cell Lung Cancer With PD-L1 Expression ≥ 1%\nEstimated primary com
 pletion: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06561386
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818070-2656@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:ONO-4578: Phase 3 readout est. (NCT07818070)
DESCRIPTION:ONO-4578\, phase 3\, Gastric Cancer.\nStudy: A Trial of ONO-457
 8 Versus Placebo in Combination With Nivolumab and Chemotherapy in Partici
 pants With Gastric Cancer\, Esophagogastric Junction Cancer\, or Esophagea
 l Adenocarcinoma\nEstimated primary completion: January 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ono-4578#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07818070
URL:https://assetmemo.bio/drug/ono-4578#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A Study to Evaluate the Safety\,
  Tolerability\, Drug Levels\, and Preliminary Efficacy of BMS-986507 Combi
 nations in Adult Participants With Advanced Solid Tumors\nEstimated primar
 y completion: 26 February 2031. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06618287
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1974@assetmemo.bio
DTSTAMP:20261121T005612Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
